TWI415839B - 作為pgds抑制劑之嘧啶醯胺化合物 - Google Patents

作為pgds抑制劑之嘧啶醯胺化合物 Download PDF

Info

Publication number
TWI415839B
TWI415839B TW095136806A TW95136806A TWI415839B TW I415839 B TWI415839 B TW I415839B TW 095136806 A TW095136806 A TW 095136806A TW 95136806 A TW95136806 A TW 95136806A TW I415839 B TWI415839 B TW I415839B
Authority
TW
Taiwan
Prior art keywords
carboxylic acid
decylamine
group
pyrimidine
fluorophenyl
Prior art date
Application number
TW095136806A
Other languages
English (en)
Chinese (zh)
Other versions
TW200812977A (en
Inventor
Suzanne C Aldous
John Ziqi Jiang
Jinqi Lu
Liang Ma
Lan Mu
Harry Randall Munson
Jeffrey Stephen Sabol
Sukanthini Thurairatnam
Christopher Loren Vandeusen
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of TW200812977A publication Critical patent/TW200812977A/zh
Application granted granted Critical
Publication of TWI415839B publication Critical patent/TWI415839B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095136806A 2005-10-04 2006-10-04 作為pgds抑制劑之嘧啶醯胺化合物 TWI415839B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72357005P 2005-10-04 2005-10-04

Publications (2)

Publication Number Publication Date
TW200812977A TW200812977A (en) 2008-03-16
TWI415839B true TWI415839B (zh) 2013-11-21

Family

ID=37635758

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095136806A TWI415839B (zh) 2005-10-04 2006-10-04 作為pgds抑制劑之嘧啶醯胺化合物

Country Status (27)

Country Link
US (1) US8202863B2 (cg-RX-API-DMAC7.html)
EP (1) EP1937652B1 (cg-RX-API-DMAC7.html)
JP (1) JP5452925B2 (cg-RX-API-DMAC7.html)
KR (1) KR101457966B1 (cg-RX-API-DMAC7.html)
CN (2) CN101538246B (cg-RX-API-DMAC7.html)
AR (1) AR056871A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006299428B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0616815A2 (cg-RX-API-DMAC7.html)
CA (1) CA2624749C (cg-RX-API-DMAC7.html)
CR (1) CR9832A (cg-RX-API-DMAC7.html)
DO (1) DOP2006000210A (cg-RX-API-DMAC7.html)
EC (1) ECSP088335A (cg-RX-API-DMAC7.html)
ES (1) ES2514471T3 (cg-RX-API-DMAC7.html)
IL (1) IL190411A (cg-RX-API-DMAC7.html)
MA (1) MA29925B1 (cg-RX-API-DMAC7.html)
MY (1) MY151172A (cg-RX-API-DMAC7.html)
NO (1) NO20082000L (cg-RX-API-DMAC7.html)
NZ (1) NZ567208A (cg-RX-API-DMAC7.html)
PE (2) PE20110118A1 (cg-RX-API-DMAC7.html)
RU (1) RU2420519C2 (cg-RX-API-DMAC7.html)
SG (1) SG166121A1 (cg-RX-API-DMAC7.html)
TN (1) TNSN08104A1 (cg-RX-API-DMAC7.html)
TW (1) TWI415839B (cg-RX-API-DMAC7.html)
UA (1) UA93213C2 (cg-RX-API-DMAC7.html)
UY (1) UY29840A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007041634A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200802222B (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759350B2 (en) * 2005-09-15 2010-07-20 Orchid Research Laboratories Ltd. Pyrimidine carboxamides
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
MX2008013194A (es) 2006-04-11 2008-12-01 Vertex Pharma Composiciones utiles como inhibidores de canales de sodio regulados por voltaje.
CA2672373C (en) 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
JP2010519328A (ja) 2007-02-26 2010-06-03 ファイザー・プロダクツ・インク H−pgdsの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンd2が媒介する疾患の治療のためのそれらの使用
ES2748599T3 (es) 2007-08-27 2020-03-17 Dart Neuroscience Cayman Ltd Compuestos terapéuticos de isoxazol
US8779197B2 (en) 2007-10-11 2014-07-15 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
WO2009049181A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
US8519137B2 (en) 2007-10-11 2013-08-27 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
CA2703220A1 (en) * 2007-11-13 2009-05-22 Pfizer Global Research And Development Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
ES2528129T3 (es) * 2008-02-06 2015-02-04 Msd K.K. Derivado de sulfonil piperacina sustituido en la posición 3
AU2009246446B2 (en) * 2008-05-13 2014-06-26 Cayman Chemical Company, Incorporated Methods for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase
CA2724998A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
JP2011524894A (ja) 2008-06-18 2011-09-08 ファイザー・リミテッド ニコチンアミド誘導体
AP3272A (en) 2008-09-22 2015-05-31 Cayman Chem Co Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prosaglandin D2 mediated diseases
KR101367057B1 (ko) 2009-03-17 2014-02-25 (주)아모레퍼시픽 피부 자극 완화용 조성물
WO2010056044A2 (ko) * 2008-11-11 2010-05-20 (주)아모레퍼시픽 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물
KR101252335B1 (ko) 2009-07-16 2013-04-08 (주)아모레퍼시픽 피부 노화 방지용 조성물
RU2496778C2 (ru) 2009-03-09 2013-10-27 Тайхо Фармасьютикал Ко., Лтд. Пиперазиновое соединение, ингибирующее простагландин-d-синтазу
PH12012501385A1 (en) 2010-01-22 2014-10-22 Taiho Pharmaceutical Co Ltd Piperazine compound having a pgds inhibitory effect
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
US9199976B2 (en) 2010-06-01 2015-12-01 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
CN106943407A (zh) * 2010-07-26 2017-07-14 赛诺菲 苯基噁二唑衍生物在制备治疗变应性或炎性疾病的药物中的用途
TW201217335A (en) 2010-09-07 2012-05-01 Taiho Pharmaceutical Co Ltd Prostaglandin d synthase inhibitory piperidine compounds
KR101271223B1 (ko) 2011-01-27 2013-06-07 한국과학기술연구원 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제
EP2800568A4 (en) * 2012-01-06 2015-06-10 Univ South Florida COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR
ES2640049T3 (es) * 2012-08-24 2017-10-31 Sunshine Lake Pharma Co., Ltd. Derivados de 3,6-dihidropirimidina 2,4,5,6-sustituidos como inhibidores de la polimerasa del virus de la hepatitis B (VHB) para el tratamiento de, por ejemplo, la hepatitis crónica
WO2017103851A1 (en) 2015-12-17 2017-06-22 Astex Therapeutics Limited Quinoline-3-carboxamides as h-pgds inhibitors
US10669270B2 (en) * 2016-03-14 2020-06-02 Emory University Amide-sulfamide derivatives, compositions, and uses related to CXCR4 inhibition
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
CA3066979A1 (en) 2017-06-13 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as h-pgds inhibitors
US11357759B2 (en) 2017-10-29 2022-06-14 China Medical University Composition including ADAM9 inhibitor and the use thereof
CN111479814A (zh) 2017-12-13 2020-07-31 葛兰素史密斯克莱知识产权发展有限公司 作为h-pgds抑制剂的稠合的吡啶
IL277455B2 (en) * 2018-03-23 2024-05-01 Step Pharma S A S Aminopyrimidine derivatives as ctps1 inhibitors
BR112021008976A2 (pt) 2018-11-08 2021-08-03 Glaxosmithkline Intellectual Property Development Limited compostos químicos
AU2021272972A1 (en) * 2020-05-13 2022-12-08 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
WO2021256569A1 (ja) 2020-06-19 2021-12-23 佐藤製薬株式会社 H-pgdsを阻害する縮環化合物
US12331046B2 (en) * 2020-10-23 2025-06-17 Nimbus Clotho, Inc. CTPS1 inhibitors and uses thereof
CN113004208A (zh) * 2021-03-08 2021-06-22 沈阳药科大学 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用
JP2024540477A (ja) * 2021-11-17 2024-10-31 シーエイチディーアイ ファウンデーション,インコーポレーテッド ハンチントン病を治療するためのhttモジュレータとしてのn-(2h-インダゾール-5-イル)ピラジン-2-カルボキサミド誘導体及び類似化合物
WO2023113023A1 (ja) 2021-12-17 2023-06-22 佐藤製薬株式会社 H-pgdsを阻害するアザインドール誘導体

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd N―(1h―テトラゾール―5―イル)―2―フェニル―5―ピリミジンカルボキシアミド類及びその合成用中間体
WO1995025723A1 (en) * 1994-03-18 1995-09-28 Agrevo Uk Limited Anilide derivatives as fungicides
WO2004072069A1 (en) * 2003-02-14 2004-08-26 Glaxo Group Limited Carboxamide derivatives
WO2005032493A2 (en) * 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
EP1553089A1 (en) * 2002-07-30 2005-07-13 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
US20050165028A1 (en) * 2004-01-23 2005-07-28 Norman Mark H. Vanilloid receptor ligands and their use in treatments

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2934543A1 (de) * 1979-08-27 1981-04-02 Basf Ag, 6700 Ludwigshafen Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide
JP2000226372A (ja) * 1999-02-01 2000-08-15 Nippon Soda Co Ltd アミド化合物、その製造方法及び農園芸用殺虫剤
AU7315700A (en) * 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
JP2003112985A (ja) 2001-10-01 2003-04-18 Nre Happiness Kk 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット
JPWO2004011430A1 (ja) * 2002-07-25 2005-11-24 アステラス製薬株式会社 ナトリウムチャネル阻害剤
PT1471057E (pt) * 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd N―(1h―テトラゾール―5―イル)―2―フェニル―5―ピリミジンカルボキシアミド類及びその合成用中間体
WO1995025723A1 (en) * 1994-03-18 1995-09-28 Agrevo Uk Limited Anilide derivatives as fungicides
EP1553089A1 (en) * 2002-07-30 2005-07-13 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
WO2004072069A1 (en) * 2003-02-14 2004-08-26 Glaxo Group Limited Carboxamide derivatives
WO2005032493A2 (en) * 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
US20050165028A1 (en) * 2004-01-23 2005-07-28 Norman Mark H. Vanilloid receptor ligands and their use in treatments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Moorthy et, al. "Inhibitors of NF-KB and AP-1 Gene Expression: SAR Studies on the Pyrimidine Portion of 2-Chloro-4-trifluoromethylpyrimidine-5-[N-(3¢,5¢-bis(trifluoromethyl)-phenyl)carboxamide]." Journal of Medicinal Chemistry. Vol 4., 2000, P3995~4004 *

Also Published As

Publication number Publication date
ECSP088335A (es) 2008-05-30
JP5452925B2 (ja) 2014-03-26
IL190411A0 (en) 2008-11-03
MY151172A (en) 2014-04-30
SG166121A1 (en) 2010-11-29
DOP2006000210A (es) 2007-06-15
KR101457966B1 (ko) 2014-11-04
CA2624749A1 (en) 2007-04-12
TW200812977A (en) 2008-03-16
US8202863B2 (en) 2012-06-19
NO20082000L (no) 2008-06-09
WO2007041634A1 (en) 2007-04-12
ZA200802222B (en) 2009-09-30
MA29925B1 (fr) 2008-11-03
CA2624749C (en) 2011-08-16
PE20070589A1 (es) 2007-06-22
KR20080050611A (ko) 2008-06-09
UY29840A1 (es) 2007-05-31
RU2008117170A (ru) 2009-11-10
CR9832A (es) 2008-06-18
RU2420519C2 (ru) 2011-06-10
ES2514471T3 (es) 2014-10-28
TNSN08104A1 (en) 2009-07-14
NZ567208A (en) 2011-03-31
AU2006299428B2 (en) 2012-04-26
CN101538246A (zh) 2009-09-23
BRPI0616815A2 (pt) 2011-07-05
JP2009510170A (ja) 2009-03-12
AU2006299428A1 (en) 2007-04-12
AR056871A1 (es) 2007-10-31
US20080227782A1 (en) 2008-09-18
EP1937652A1 (en) 2008-07-02
EP1937652B1 (en) 2014-07-30
IL190411A (en) 2013-09-30
UA93213C2 (en) 2011-01-25
PE20110118A1 (es) 2011-03-08
CN101282943A (zh) 2008-10-08
CN101538246B (zh) 2014-07-16

Similar Documents

Publication Publication Date Title
TWI415839B (zh) 作為pgds抑制劑之嘧啶醯胺化合物
TWI430994B (zh) 作為pgds抑制劑之嘧啶醯肼化合物
JP5711270B2 (ja) アポトーシスシグナル調節キナーゼ1阻害剤
US20070213338A1 (en) Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain
JP2002308875A (ja) エンドセリンの活性を調節するスルホンアミドおよびそれらの誘導体
CN102395584A (zh) 用于代谢疾病治疗的化合物
EP1701944A2 (en) 2-(amino-substituted)-4-aryl pyramidines and related compounds useful for treating inflammatory diseases
US20250059154A1 (en) Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
TW201400464A (zh) 新穎嘧啶化合物及含有此之醫藥
TW202024020A (zh) 治療神經退化性疾病之方法
CN115515948B (zh) Phd抑制剂化合物、组合物和用途
CN103443107B (zh) 噻唑并嘧啶化合物
HK1136162A (en) Pyrimidine amide compounds as pgds inhibitors
HK1139413A (en) Pyrimidine hydrazide compounds as pgds inhibitors

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees